TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04243096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise-based Physical Therapy
Description: Exercises for pain modulation, strengthening, and neuromuscular control
Study: NCT00565747

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test culture
Description: A standard culture medium with added GM-CSF (ready-to-use)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control culture
Description: The same standard culture medium, but without any additions (ready-to-use)
Study: NCT02918266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: Scopolamine subcutaneous injection
Study: NCT02551588

Intervention type: PROCEDURE
Intervention: Valvular aortic stenosis surgery
Description: Dilatation of Valvular aortic stenosis
Study: NCT02918266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: Scopolamine subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: Scopolamine subcutaneous injection
Study: NCT04125602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat low carbohydrate diet
Description: Throughout the 6-day intervention, participants are provided with a high fat, low carbohydrate diet (HF-LCD), including a 3-day diet in which the percentage of fat, protein and carbohydrate is 60%, 15% and 25% respectively while the three macronutrients in the other 3-day diet account for 70%, 15% and 15% respectively. The sequencing of the two diets will be randomized.
Study: NCT02918266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: Scopolamine subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: Scopolamine subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: Scopolamine subcutaneous injection
Study: NCT04125602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat low carbohydrate diet
Description: Throughout the 6-day intervention, participants are provided with a high fat, low carbohydrate diet (HF-LCD), including a 3-day diet in which the percentage of fat, protein and carbohydrate is 60%, 15% and 25% respectively while the three macronutrients in the other 3-day diet account for 70%, 15% and 15% respectively. The sequencing of the two diets will be randomized.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fat high carbohydrate diet
Description: Throughout the 6-day intervention, participants are provided with a low fat, high carbohydrate diet (LF-HCD), including a 3-day diet in which the percentage of fat, protein and carbohydrate is 20%, 15% and 65% respectively while the three macronutrients in the other 3-day diet account for 10%, 15% and 75% respectively. The sequencing of the two diets will be randomized.
Study: NCT04125602

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fat high carbohydrate diet
Description: Throughout the 6-day intervention, participants are provided with a low fat, high carbohydrate diet (LF-HCD), including a 3-day diet in which the percentage of fat, protein and carbohydrate is 20%, 15% and 65% respectively while the three macronutrients in the other 3-day diet account for 10%, 15% and 75% respectively. The sequencing of the two diets will be randomized.
Study: NCT02940548

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine GITS
Description: Nifedipine GITS 30\~60mg/day for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine besylate
Description: Amlodipine besylate 5\~10mg/day for 8 weeks
Study: NCT02358187

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC
Description: Poly-ICLC is administered intramuscularly (i.m.) using sterile technique, as supplied from the vial, and in the amount prescribed for the participant's weight. Patients should receive a dose of acetaminophen (15 mg/kg up to a max of 1000 mg) 30-60 minutes before each poly-ICLC administration. The poly-ICLC treatments will be administered immediately following the vaccine. Patients/parents will be asked to report any temperature elevations and side effects after each treatment.
Study: NCT04570202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR
Description: The EMDR therapy is organized in eight different phases, requiring attending multiple sessions, usually 12 separate sessions.
Study: NCT01459120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Door-to-door
Description: Health workers propose the integrated service package including VCT at the peoples' homes (home-based testing).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pitso
Description: Health care workers propose the integrated service package including VCT through community gatherings (Pitso).
Study: NCT01101685

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 7 days dosing of 10mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7 days dosing at 10mg daily
Study: NCT00356317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally informed therapy for schizophrenia (CIT-S)
Description: This family therapy consists of 15 video-taped, therapy sessions, each lasting approximately 75 minutes. The 15-session treatment will be broken down into five segments (each lasting approximately three sessions) with the following goals: 1) Fortify a strong sense of family unity; 2) educate about schizophrenia; 3) foster adaptive use of cultural, spiritual and/or existential beliefs in conceptualizing and coming to terms with schizophrenia; 4) teach effective communication training techniques; and 5) and teach useful problem solving strategies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation treatment as usual
Description: This family therapy consists of three weekly sessions focusing on education about schizophrenia.
Study: NCT04275817

Intervention type: OTHER
Intervention: Data collection
Description: Telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site

Intervention type: OTHER
Intervention: Data collection
Description: Telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site

Intervention type: OTHER
Intervention: Data collection
Description: Telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
Study: NCT00538213

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix™
Description: Single dose, Intramuscular injection
Study: NCT00538213

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix™
Description: Single dose, Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Bio's Influenza Vaccine GSK576389A
Description: Single dose, Intramuscular injection
Study: NCT01505101

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement
Description: MORE is a multimodal, dual-process group intervention involving mindfulness training, cognitive restructuring, and positive emotion induction. MORE consists of eight, weekly, two-hour group sessions led by a trained therapist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Support Group (SG)
Description: The control arm will participate in a time-matched, conventional SG led by a Master's level therapist, discussing topics pertinent to chronic pain and opioid misuse. The SG format is adapted from the support group detailed in the evidence-based, Matrix Intensive Outpatient Treatment manual. The SG consists of eight, weekly, two-hour sessions.
Study: NCT05307614

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moksi® 400mg Tablet
Description: Single dose of Moxifloxacin 400 mg Tablet was administered after a 10-hour overnight fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moksi® 400mg Tablet
Description: Single dose of Moxifloxacin 400 mg Tablet was administered after a 10-hour overnight fast.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Avelox® 400Mg Tablet
Description: Single dose of Moxifloxacin 400 mg Tablet was administered after a 10-hour overnight fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Avelox® 400Mg Tablet
Description: Single dose of Moxifloxacin 400 mg Tablet was administered after a 10-hour overnight fast.
Study: NCT05714735

Intervention type: RADIATION
Intervention: Cerebral Venography
Description: Cerebral Venography Observation by DSA examinations
Study: NCT02318381

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dissection of the superior transverse scapular ligament
Description: After treatment of the rotator cuff tear, the arthroscopic procedure will also proceed with the dissection of the superior transverse scapular ligament, in order to release pressure from the suprascapular nerve.
Study: NCT04618458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Power to Prevent
Description: Lifestyle diabetes prevention intervention based on the National Diabetes Prevention Program and tailored for African American families. The intervention will be delivered using telehealth and small group videoconferencing.
Study: NCT03444701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7130
Description: Starting dose of 25 μg/m\^2 on Day 1 and Day 15 of Cycle 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7130
Description: Starting dose is lower than one at which the first DLT was observed in the 2-week regimen administered on Day 1 of Cycle 1.
Study: NCT01748318

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: New Mexico Honey
Description: Apply 15 ml of NM Honey to CA-MRSA Abscess compare to standard antibiotic treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New Mexico Honey
Description: Apply 15 ml of NM Honey to CA-MRSA Abscess compare to standard antibiotic treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bactrim DS
Description: Bactrim DS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bactrim DS
Description: Bactrim DS
Study: NCT04143919

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NYHA assessment
Description: The New York Heart Association (NYHA) functional classification of HF

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serum NT-proBNP concentration
Description: Subjects with NYHA score ≥ II will undergo a rapid, on site serum NT-proBNP test on the same day of the visit. Roche CARDIAC proBNP+ test, using the Cobas h 232 device, is a quantitative immunological test for the determination of NT-proBNP in heparinized venous blood.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transthoracic Ecocardiogram
Description: Subjects with a serum NT-proBNP result of ≥ 125 pg/mL at Visit 1 will be referred to a study cardiologist for a transthoracic echocardiogram to assess LVEF and relevant structural heart disease
Study: NCT02918266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 DIC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 DIC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 DIC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 DIC
Study: NCT02519452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab Subcutaneous (SC) Administration
Description: Participants will receive Daratumumab mixed with rHuPH20 in part 1 and co-formulated with rHuPH20 in part 2 and part 3 administered via SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.
Study: NCT02918266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 DIC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 DIC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 DIC
Study: NCT02918266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 DIC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 DIC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 DIC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 DIC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil over-encapsulated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil over-encapsulated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil over-encapsulated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil over-encapsulated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil over-encapsulated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil over-encapsulated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil over-encapsulated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil over-encapsulated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil over-encapsulated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil over-encapsulated tablet
Study: NCT02519452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Hyaluronidase [rHuPH20]) SC Administration
Description: Participants will receive Recombinant Human Hyaluronidase \[rHuPH20\]) mixed with Daratumumab in part 1 and co-formulated with Daratumumab in part 2 and part 3 administered as SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.
Study: NCT02830152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAAO
Description: The left atrial appendage is occluded with the AMPLATZER™ Amulet™ device, which offers a conformable disc and lobe designed for complete occlusion of the left atrial appendage.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical Therapy
Description: Available options included in Medical therapy are: anticoagulation with OAC or NOAC, antiplatelet therapy (including monotherapy and dual antiplatelet therapy) and no pharmacological antithrombotic therapy.
Study: NCT05823350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal massage
Description: Abdominal massage after colonoscopy
Study: NCT02787161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemodiafiltration
Description: High volume online HDF

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodialysis
Description: High-flux HD
Study: NCT02305485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeoVas BCS
Description: Subjects receiving NeoVas BCS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE PRIME EECSS
Description: Subjects receiving XIENCE PRIME EECSS
Study: NCT02651480

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant-based diet
Description: Weekly instructions will be given to the participants in the intervention group about following vegan diet.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Unrestricted diet with no instruction.
Study: NCT02118935

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Previously marketed cow's mlik-based infant formula

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Marketed cow's milk-based infant formula with prebiotics
Study: NCT03833102

Intervention type: OTHER
Intervention: biological analysis
Description: ST types will be determined for all individualized bacterial strains. For all the bacterial strains, RNAs expression will be analyzed at three different growth phases: early exponential phase, mid exponential phase and early stationary phase. Expression of RNAIII and SprD will be evaluated by quantitative polymerase chain reaction.

Intervention type: OTHER
Intervention: biological analysis
Description: ST types will be determined for all individualized bacterial strains. For all the bacterial strains, RNAs expression will be analyzed at three different growth phases: early exponential phase, mid exponential phase and early stationary phase. Expression of RNAIII and SprD will be evaluated by quantitative polymerase chain reaction.
Study: NCT01499108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Subcutaneous injection of liraglutide at doses of 0.6, 1.2, and 1.8 mg once daily during the 49 days duration of the study
Study: NCT02869620

Intervention type: OTHER
Intervention: Data collection
Study: NCT04408274

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Processing Training

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Study: NCT02079324

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GX-051
Description: intratumoral injection
Study: NCT02669524

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY2409021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY2409021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY2409021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY2409021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY2409021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY2409021

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY2409021 placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY2409021 placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY2409021 placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY2409021 placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY2409021 placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY2409021 placebo

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OGTT

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: OGTT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OGTT

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: OGTT
Study: NCT04448496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone implant
Description: Dexamethasone 0.7mg is injected into the vitreous cavity through the pars plana using applicator for diabetic macular edema.
Study: NCT01501110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: in infusion of 1200 mg of n-acetylcysteine twice a day for 48 hours
Study: NCT04253353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis
Description: 61 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: 10 mg tablet
Study: NCT02265406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Infective Agents

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03836924

Intervention type: DRUG
Intervention: Perampanel
Description: Perampanel tablets.
Study: NCT03901391

Intervention type: DIAGNOSTIC_TEST
Intervention: Whole Exome Sequencing
Description: Whole Exome Sequencing
Study: NCT01584895

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation
Description: A standard cardiac rehabilitation program consisting of 3 days per week of supervised exercise and education.
Study: NCT00949988

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib and Rituximab
Description: In Phase I, subjects will be enrolled into a 3+3 dose escalation scheme with two dasatinib cohort doses of 70 mg QD and 100 mg QD to be given continuously during each 28-day cycle. All subjects will also receive rituximab 500 mg/m2 on day 1 of each cycle (375 mg/m2 on day 1 of cycle 1 only). There will be a pre-phase for each dose cohort when subjects will receive single-agent dasatinib from days -7 to -1 to allow for PK and PD assessment. Cohorts will be assessed for dose-limiting toxicities for two cycles before accrual of additional

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib and Rituximab
Description: In Phase I, subjects will be enrolled into a 3+3 dose escalation scheme with two dasatinib cohort doses of 70 mg QD and 100 mg QD to be given continuously during each 28-day cycle. All subjects will also receive rituximab 500 mg/m2 on day 1 of each cycle (375 mg/m2 on day 1 of cycle 1 only). There will be a pre-phase for each dose cohort when subjects will receive single-agent dasatinib from days -7 to -1 to allow for PK and PD assessment. Cohorts will be assessed for dose-limiting toxicities for two cycles before accrual of additional
Study: NCT06193031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16TR
Description: Administered as inhalation using a Philips Micro device inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16TR
Description: Administered as inhalation using a Philips Micro device inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C16TR
Description: Administered as inhalation using a Philips Micro device inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phosphate buffered saline (PBS) administered using Philips Micro device inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phosphate buffered saline (PBS) administered using Philips Micro device inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Phosphate buffered saline (PBS) administered using Philips Micro device inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyvaso®
Description: Administered as inhalation.
Study: NCT02165514

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lunar iDXA x-ray scan
Description: Subjects will lay either on their back or side depending whether subject has kyphosis or scoliosis. After the DEXA scan the computer will calculate the Cobb angle. The calculation of Cobb angle from the DEXA scan will be compared to the conventional spine x-ray.
Study: NCT01625481

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seal-V
Description: Seal-V is applied adjunctively to cover the suture lines.